Vnitr Lek 2009, 55(12):1135-1140

Nuclear receptors gene polymorphisms and risk of restenosis and clinical events following coronary stenting

P. Neugebauer1,*, M. Goldbergová-Pávková2, P. Kala1, O. Boček1, P. Jeřábek1, M. Poloczek1, M. Vytiska1, J. Pařenica1, R. Mikulík3, J. Jarkovský4, B. Semrád1, J. Špinar1, A. Vašků2
1 Interní kardiologická klinika Lékařské fakulty MU a FN Brno, pracoviště Bohunice, přednosta prof. MUDr. Jindřich Špinar, CSc., FESC
2 Ústav patologické fyziologie Lékařské fakulty MU Brno, přednostka prof. MUDr. Anna Vašků, CSc.
3 Neurologická klinika Lékařské fakulty MU a FN sv. Anny Brno, přednosta prof. MUDr. Ivan Rektor, CSc.
4 Institut biostatistiky a analýz Lékařské a Přírodovědecké fakulty MU Brno, přednosta doc. RNDr. Ladislav Dušek, Ph.D.

Introduction:
Hereditary factors connected with inflammation and fibroproliferation may play important role in restenotic process after coronary stenting. Peroxisome proliferator-activated receptors (PPAR) and retinoic X receptors (RXR) regulate the transcription of crucial genes involved in the glucose and lipid metabolism, inflammation and cell differentiation.

Methods:
In our angiographic and clinical study we assessed the association of gene polymorphisms of L162V for PPAR-α, C161T for PPAR-γ and A(39526)AA for RXR-α with the risk of restenosis and cardiac events after coronary stenting. Primary endpoint was diameter stenosis ≥ 50% at follow-up angiography. Secondary endpoints were death, myocardial infarction and/or target lesion revascularisation at 12 months, and clinical restenosis. The results were adjusted for known predictors of restenosis. The genotypes were analysed by polymerase chains reaction (PCR) and restriction fragment length polymorphism (RFLP) methods.

Results:
Control angiography was performed in 477 of 565 patients (84.4%) with following restenosis rates in genotype subgroups: CC 29.0% vs GC/GG 22.6% (p = 0.33) in L162V, CC 29.9% vs TC/TT 24.6% (p = 0.24) in C161T and A/A 26.9 % vs A/AA + AA/AA 35.0 % (p = 0.14) in A(39526)AA polymorphisms. The T allele of C161T polymorphism was associated with lower frequency of clinical restenosis (p = 0.015).

Conclusion:
We could not find an association of L162V PPAR-α, C161T PPAR-γ and A(39526)AA RXR-α gene polymorphisms with angiographic in-stent restenosis or major cardiac events. However, we found the relationship between C161T PPAR-γ polymorphism and clinical restenosis deserving further study.

Keywords: in-stent restenosis; gene polymorphism; nuclear receptors

Received: May 26, 2009; Accepted: August 26, 2009; Published: December 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Neugebauer P, Goldbergová-Pávková M, Kala P, Boček O, Jeřábek P, Poloczek M, et al.. Nuclear receptors gene polymorphisms and risk of restenosis and clinical events following coronary stenting. Vnitr Lek. 2009;55(12):1135-1140.
Download citation

References

  1. Antoniucci D, Valenti R, Santoro GM et al. Restenosis after coronary stenting in current clinical practice. Am Heart J 1998; 135: 510-518. Go to original source... Go to PubMed...
  2. Kastrati A, Schömig A, Elezi S et al. Predictive factors of restenosis after coronary stent placement. J Am Coll Cardiol 1997; 30: 1428-1436. Go to original source... Go to PubMed...
  3. Cutlip DE, Chauhan MS, Baim DS et al. Clinical restenosis after coronary stenting: perspectives from multicenter clinical trials. J Am Coll Cardiol 2002; 40: 2082-2089. Go to original source... Go to PubMed...
  4. Mercado N, Boersma E, Wijns W et al. Clinical and quantitative coronary angiographic predictors of coronary restenosis: a comparative analysis from the balloon-to-stent era. J Am Coll Cardiol 2001; 38: 645-652. Go to original source... Go to PubMed...
  5. Kastrati A, Mehilli J, Dirschinger J et al. Restenosis after coronary placement of various stent types. Am J Cardiol 2001; 87: 34-39. Go to original source... Go to PubMed...
  6. Vojáček J. Restenosis after coronary angioplasty: status in 1994. Vnitř Lék 1995; 41: 325-331. Go to PubMed...
  7. Kastrati A, Dirschinger I, Schömig A. Genetic risk factors and restenosis after percutaneous coronary interventions. Herz 2000; 25: 34-46. Go to original source... Go to PubMed...
  8. Agema WR, Jukema JW, Pimstone SN et al. Genetic aspects of restenosis after percutaneous coronary interventions: towards more tailored therapy. Eur Heart J 2001; 22: 2058-2074. Go to original source... Go to PubMed...
  9. Gürlek A, Güleç S, Karabulut H et al. Relation between the insertion/deletion polymorphism of the angiotensin I converting enzyme gene and restenosis after coronary stenting. J Cardiovasc Risk 2000; 7: 403-407. Go to original source... Go to PubMed...
  10. Koch W, Kastrati A, Mehilli J et al. Insertion/deletion polymorphism of the angiotensin I-converting enzyme gene is not associated with restenosis after coronary stent replacement. Circulation 2000; 102: 197-202. Go to original source... Go to PubMed...
  11. von Beckerath N, Koch W, Mehilli J et al. Glycoprotein Ia gene C807T polymorphism and risk for major adverse cardiac events within the first 30 days after coronary artery stenting. Blood 2000; 95: 3297-3301. Go to original source...
  12. Rudez G, Pons D, Leebeek F et al. Platelet receptor P2RY12 haplotypes predict restenosis after percutaneous coronary interventions. Hum Mutat 2008; 29: 375-380. Go to original source... Go to PubMed...
  13. Böttiger C, Kastrati A, Koch W et al. Polymorphism of platelet glycoprotein IIb and risk of thrombosis and restenosis after coronary stent placement. Am J Cardiol 1999; 84: 987-991. Go to original source... Go to PubMed...
  14. Monraats PS, Pires NM, Agema WR et al. Genetic inflammatory factors predict restenosis after percutaneous coronary interventions. Circulation 2005; 112: 2417-2425. Go to original source... Go to PubMed...
  15. Gomma AH, Elrayess MA, Knight CJ et al. The endothelial nitric oxide synthase (Glu298Asp and -786T>C) gene polymorphisms are associated with coronary in-stent restenosis. Eur Heart J 2002; 23: 1955-1962. Go to original source... Go to PubMed...
  16. Bienertová-Vasků JA, Hlinomaz O, Vasků A. Are common leptin promoter polymorphisms associated with restenosis after coronary stenting? Heart Vessels 2007; 22: 310-315. Go to original source... Go to PubMed...
  17. Bishop-Bailey D. Peroxisome proliferator-activated receptor in the cardiovascular system. Br J Pharmacol 2000; 129: 823-834. Go to original source... Go to PubMed...
  18. Brown J, Plutzky J. Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets. Circulation 2007; 115: 518-533. Go to original source... Go to PubMed...
  19. Marx N, Schönbeck U, Lazar MA et al. Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ Res 1998; 83: 1097-1103. Go to original source... Go to PubMed...
  20. Choi D, Kim SK, Choi SH et al. Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes. Diabetes Care 2004; 27: 2654-2660. Go to original source... Go to PubMed...
  21. Takagi T, Akasaka T, Yamamuro A et al. Troglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with non-insulin dependent diabetes mellitus: a serial intravascular ultrasound study. J Am Coll Cardiol 2000; 36: 1529-1535. Go to original source... Go to PubMed...
  22. Wang XL, Oosterhof J, Duarte N. Peroxisome proliferator-activated receptor gamma C161→T polymorphism and coronary artery disease. Cardiovasc Res 1999; 44: 588-594. Go to original source... Go to PubMed...
  23. Chao TH, Li YH, Chen JH et al. The 161TT genotype in the exon 6 of the peroxisome-proliferator-activated receptor gamma gene is associated with premature acute myocardial infarction and increased lipid peroxidation in habitual heavy smokers. Clin Sci 2004; 107: 461-466. Go to original source... Go to PubMed...
  24. Tai ES, Collins D, Robins SJ et al. The L162V polymorphism at the peroxisome proliferator activated receptor alpha locus modulates the risk of cardiovascular events associated with insulin resistance and diabetes mellitus: the Veterans Affairs HDL Intervention Trial (VA-HIT). Atherosclerosis 2006; 187: 153-160. Go to original source... Go to PubMed...
  25. Robitaille J, Brouillette C, Houde A et al. Association between the PPARalpha-L162V polymorphism and components of the metabolic syndrome. J Hum Genet 2004; 49: 482-489. Go to original source... Go to PubMed...
  26. Goldbergová M, Špinarová L, Špinar J et al. Intron Retinoic X Receptor Alpha Polymorphism in Chronic Heart Failure. Atheroscler 2002; 3 (Suppl 2): 115-116. Go to original source...
  27. Haraguchi G, Suzuki J, Kosuge H et al. A new RXR agonist, HX630, suppresses intimal hyperplasia in a mouse blood flow cessation model. J Mol Cell Cardiol 2006; 41: 885-892. Go to original source... Go to PubMed...
  28. Ahuja HS, Szanto A, Nagy L et al. The retinoid X receptor and its ligands: versatile regulators of metabolic function, cell differentiation and cell death. J Biol Regul Homeost Agents 2003; 17: 29-45. Go to PubMed...
  29. Meredith D, Panchatcharam M, Miriyala S et al. Dominant-negative loss of PPAR{gamma} function enhances smooth muscle cell proliferation, migration, and vascular remodeling. Arterioscler Thromb Vasc Biol 2009; 29: 465-471. Go to original source... Go to PubMed...
  30. Gizard F, Bruemmer D. Transcriptional control of vascular smooth muscle cell proliferation by peroxisome proliferator-activated receptor-gamma: therapeutic implications for cardiovascular diseases. PPAR Res 2008; 2008: 429123. Go to original source... Go to PubMed...
  31. Koch W, Jung V, von Beckerath N et al. Peroxisome proliferator-activated receptor gamma gene polymorphisms and restenosis in diabetic patients after stenting in coronary arteries. Diabetologia 2004; 47: 1126-1127. Go to original source...
  32. Bonnici F, Keavney B, Collins R et al. Angiotensin converting enzyme insertion or deletion polymorphism and coronary restenosis: meta-analysis of 16 studies. BMJ 2002; 325: 517-520. Go to original source... Go to PubMed...
  33. Tiroch K, Koch W, von Beckerath N et al. Heme oxygenase-1 gene promoter polymorphism and restenosis following coronary stenting. Eur Heart J 2007; 28: 968-973. Go to original source... Go to PubMed...
  34. Krönke G, Kadl A, Ikonomu E et al. Expression of heme oxygenase-1 in human vascular cells is regulated by peroxisome proliferator-activated receptors. Arterioscler Thromb Vasc Biol 2007; 27: 1276-1282. Go to original source... Go to PubMed...




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.